The characteristic toughness and strength of bone result from the nature of bone matrix, the mineralized extracellular matrix produced by osteoblasts. The mechanical properties and composition of bone matrix, along with bone mass and architecture, are critical determinants of a bone's ability to resist fracture. Several regulators of bone mass and architecture have been identified, but factors that regulate the mechanical properties and composition of bone matrix are largely unknown. We used a combination of high-resolution approaches, including atomic-force microscopy, x-ray tomography, and Raman microspectroscopy, to assess the properties of bone matrix independently of bone mass and architecture. Properties were evaluated in genetically modified mice with differing levels of TGF- signaling. Bone matrix properties correlated with the level of TGF- signaling. Smad3؉͞؊ mice had increased bone mass and matrix properties, suggesting that the osteopenic Smad3؊͞؊ phenotype may be, in part, secondary to systemic effects of Smad3 deletion. Thus, a reduction in TGF- signaling, through its effector Smad3, enhanced the mechanical properties and mineral concentration of the bone matrix, as well as the bone mass, enabling the bone to better resist fracture. Our results provide evidence that bone matrix properties are controlled by growth factor signaling.osteoblast ͉ Smad3 ͉ atomic force microscopy T he ability of bones to resist fracture is determined by the bone mass and architecture, and the mechanical properties and composition of the bone matrix (1). Bone architecture is determined by cortical bone thickness, trabecular bone volume, and organization. Several signaling pathways, including estrogen, parathyroid hormone, and TGF-, have been implicated in the control of bone mass and architecture and its deregulation in metabolic bone diseases such as osteoporosis (2, 3). Much less is known about the mechanical properties and composition of bone matrix, the unique protein-and mineral-rich extracellular material produced by osteoblasts and osteocytes. However, the importance of bone matrix quality is clinically apparent in bone disorders such as osteogenesis imperfecta and osteopetrosis (4, 5). Osteopetrosis patients have increased bone fragility despite elevated bone mass (4). Presumably, bone matrix properties are highly regulated, but the regulators themselves are unknown, partly because of the inaccessibility of methods to define these properties independently of bone mass and architecture. Nevertheless, the regulation of bone matrix properties must be understood to more effectively treat bone disorders.TGF- plays stage-dependent roles in osteoblast and osteoclast differentiation. TGF- inhibits osteoblast differentiation yet stimulates the proliferation of mesenchymal progenitors, thereby expanding the cell population that will differentiate into osteoblasts (6). TGF- signals through a complex of type I and type II transmembrane serine͞threonine kinases (7). Upon ligand binding, the receptor complex phosphorylat...